Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial

Table 1 Baseline characteristics of study participants described for primary and secondary outcome measures.

	Placebo (n = 6)	Ascorbic acid (n = 5)
Male/Female (numbers)	2/4	3/2
Age (years)^b	16 (13-24)	19 (14-24)
Median nerve MNCV (m/s)^a	17.9 (6.0)	17.2 (1.7)
Median nerve minimal F response latency (ms)^a	83.8 (28.0)*	77.1 (10.6)
CMAP amplitude abductor pollicis brevis muscle (mV)^a	3.9 (1.1)	4.0 (1.2)
Three point grip (N)^a	50.9 (14.4)	73.8 (24.7)
Foot dorsiflexors (N)^a	79.5 (14.0)	91.1 (26.9)
ISS^b	2 (0-8)	3 (1-6)
CMTNS^b	10 (7-20)	13 (7-17)
ODSS^b	3 (2-4)	2 (2-4)
ALDS^a	86.8 (6.5)	89.0 (0.5)
Nine hole peg test (s)^a	26.3 (6.6)	23.5 (1.8)
50 m walking (s)^a	31.9 (2.0)	29.2 (3.2)

^a Mean (standard deviation) ^b Median (range) * n = 5
Abbreviations: ALDS = Academic Medical Centre linear disability score; CMAP = Compound muscle action potential; CMTNS = Charcot-Marie-Tooth neuropathy score; ISS = inflammatory neuropathy cause and treatment sensory sum score; MNCV = motor nerve conduction velocity; ODSS = overall disability sum score

ISSN: 1741-7015